An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
However, these won’t be available at the nearest chemist store soon
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
First launches expected in H1 2022
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
They will commercialize molnupiravir in the international markets
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Subscribe To Our Newsletter & Stay Updated
